939-P: Real-World Performance of the Guardian Connect System with Sugar.IQ
| العنوان: | 939-P: Real-World Performance of the Guardian Connect System with Sugar.IQ |
|---|---|
| المؤلفون: | Robert A. Vigersky, Pratik Agrawal, Yuxiang Zhong, Toni L. Cordero, Sinu Bessy Abraham, Francine R. Kaufman, Siddharth Arunachalam |
| المصدر: | Diabetes. 68 |
| بيانات النشر: | American Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, Continuous glucose monitoring, Endocrinology, Diabetes and Metabolism, Internal Medicine, Physical therapy, Medicine, Therapy adherence, business, Insulin dose, Glucose management, Glycemic |
| الوصف: | Background: The Guardian Connect continuous glucose monitoring (CGM) system displays current and trending sensor glucose (SG) via smartphone; records insulin, carbohydrate and exercise; and sends predictive high and low SG alerts up to one hour in advance. When used with the Sugar.IQ diabetes assistant application, personalized insights based on behavior patterns (e.g., food log or insulin dose entry) and glycemic outcomes can be tracked with the Glycemic Assist feature. Methods: System data uploaded between June-November of 2018, by 1765 individuals with diabetes were analyzed. Time in target glucose range (TIR, 70-180 mg/dL) and the Glucose Management Indicator (GMI) were compared between those who used (N=530) or did not use Sugar.IQ. Both groups had ≥5 days of SG data and similar demographic and initial glucose profiles. Results: System users had a mean GMI of 7.1%, mean±SD SG of 157.0±49.1mg/dL (8.7±2.7mmol/L), and a mean TIR of 64.5%, over the data upload period. When predictive alerts were enabled, excursions were avoided after 31% of high SG alerts and 62% of low SG alerts. Those who accessed Sugar.IQ experienced a TIR increase of 2.7% (p=0.006) and a mean SG decrease of -3.0% (p Discussion: The Guardian Connect CGM system with Sugar.IQ may advance patient understanding of glucose trends, aid in behavioral change that improves therapy adherence, and lead to better glycemic outcomes. Disclosure S. Arunachalam: Employee; Self; Medtronic. Y. Zhong: None. S. Abraham: Employee; Self; Medtronic MiniMed, Inc. P. Agrawal: Employee; Self; Medtronic MiniMed, Inc. Stock/Shareholder; Self; Medtronic. R. Vigersky: Employee; Self; Medtronic MiniMed, Inc. T.L. Cordero: Employee; Self; Medtronic. F.R. Kaufman: Employee; Self; Medtronic. |
| تدمد: | 1939-327X 0012-1797 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::242dadf80a22ff9bb606c2ea3577de0fTest https://doi.org/10.2337/db19-939-pTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........242dadf80a22ff9bb606c2ea3577de0f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 |
|---|